How Does CAR-T Therapy’s Efficacy Translate to Clinical Value for Hong Kong Patients with Refractory Hematological Malignancies, and How Can Optimized Manufacturing Help Close the Current Access Gap?. J. Med. Life Sci. [Internet]. 2026 Apr. 10 [cited 2026 Apr. 30];2(1):53-70. Available from: https://www.gbspress.com/index.php/JMLS/article/view/636